Morgenthaler Ventures

Morgenthaler Ventures is a venture capital and private equity firm that invests in IT and life sciences companies.

14 reviews

Independent rating of Morgenthaler Ventures VC fund

Overall rating:
14 reviews
Team quality
Not reviewed
Professionalism
None
Personal qualities
None
Integrity
None
Respect and decency
None
Experience
None
Relevant expertise
None
Investment process
Not reviewed
Approachability
None
Clarity of the process
None
Speed of the process
None
Responsiveness
None
Ease of the process
None
Due diligence
None
Value add
Not reviewed
Supportiveness
None
Value add beyond financing
None
Board activity
None
Terms
None
Founder friendly
None
Help with follow-up rounds
None

About Morgenthaler Ventures VC fund

Founded:
1968
Number of funds:
2
Number of investments:
347
Number of exits:
102
Headquarters:
Organization type:
Venture Capital

How Morgenthaler Ventures VC fund invests

Average ticket size:
11.9M USD
Biggest investment:
22.6M USD
Would lead round:
Yes
Would coinvest:
Yes
Countries where invested:

Portfolio - latest investments by Morgenthaler Ventures VC fund

Founders' reviews of Morgenthaler Ventures VC fund

Not reviewed
Team quality
Not reviewed
Investment process
Not reviewed
Value add
Not reviewed
Older than a year by non-portfolio founder
Pitches and Rejected but Professional
I pitched a partner after an introduction from a co-founder. It took several weeks but finally heard back. They were professional in getting back (it is 100x better to get a no than to waffle for 6 months). I have not yet received any feedback, though I asked for it. Can't say how I would give this firm negative marks. They seemed to move fast relative to other funds.
Not reviewed
Team quality
Not reviewed
Investment process
Not reviewed
Value add
Not reviewed
Older than a year by non-portfolio founder
Unlock more reviews by creating a free account
I would not recommend Rebecca Lynn on your board
Have the experience of working with a company where Lynn is a board member. The interaction by her as a board member has been the most inappropriate I have seen my career. She is not strategic, consistently undermines decisions the leadership's decisions, will pump other executives directly for information about the CEO's decisions and performance, putting the entire team in a difficult position. .
Not reviewed
Team quality
Not reviewed
Investment process
Not reviewed
Value add
Not reviewed
Older than a year by non-portfolio founder
Unlock more reviews by creating a free account
Avoid at All Costs
I was recently an executive for a company recently where Morgenthaler is an investor and board member. The company had significant growth, and where this would normally be considered a success, it caused fear and anxiety with Morgenthaler. During this process they unsuccessfully attempted to replace the CEO twice, both times failing. Unfortunately, these actions were value destroying and caused much dysfunction for the company and Founder/CEO.
Not reviewed
Team quality
Not reviewed
Investment process
Not reviewed
Value add
Not reviewed
Older than a year by non-portfolio founder
Unlock more reviews by creating a free account
Ken Gullicksen, Solid Board Member
I was a CEO and founder at a Morgenthaler-backed company, and Ken Gullicksen was our board member. Throughout several years of interactions, overall I have been satisfied with the partnership with the firm and especially with Ken. Inevitably, almost every startup goes through some growing pains, and I appreciated Ken’s flexibility, patience, and thoughtfulness in dealing with many of the issues that we encountered. Above all, I found that Ken Gullicksen tries to be fair to both the interests of the employees and founders, as well as to his VC partnership, which is definitely not always the case with venture capitalists. For these reasons, I would be happy to collaborate with Ken again in the future on my next companies.
Not reviewed
Team quality
Not reviewed
Investment process
Not reviewed
Value add
Not reviewed
Older than a year by non-portfolio founder
Unlock more reviews by creating a free account
Changes at Morgenthaler
Gary Shaffer and Greg Blonder are out of the Partnership.
Not reviewed
Team quality
Not reviewed
Investment process
Not reviewed
Value add
Not reviewed
Older than a year by non-portfolio founder
Unlock more reviews by creating a free account
They Fell Asleep!
Actually not sure if they fell asleep, or I did. Low energy
Not reviewed
Team quality
Not reviewed
Investment process
Not reviewed
Value add
Not reviewed
Older than a year by non-portfolio founder
Unlock more reviews by creating a free account
Good Experience
Pitched to KenKen Gullicksen. He was on time, asked reasonable questions and took his time understanding our product and our business model. They turned us down. It was the standard issue where they want us to be further down the road, and we want the money so that we can get there fast rather than grow organically.
Not reviewed
Team quality
Not reviewed
Investment process
Not reviewed
Value add
Not reviewed
Older than a year by non-portfolio founder
Unlock more reviews by creating a free account
Young Healthcare Care Team Definitely Not Up to Speed
They have smart guys, but not innovative thinkers and WAY too conservative on the healthcare side to do anything early-stage. If you aren't doing large scale clinical trial already, do not bother with them.
Not reviewed
Team quality
Not reviewed
Investment process
Not reviewed
Value add
Not reviewed
Older than a year by non-portfolio founder
Unlock more reviews by creating a free account
Goof Track Record. Young Guys Not Up to Snuff
David M. is an incredible individual. Truly a classy guy and a gentlemen. He build a premier firm. He has some good older partners (Bellas). Some of the younger guys are not of the same ilk. Choose partners wisely.
Not reviewed
Team quality
Not reviewed
Investment process
Not reviewed
Value add
Not reviewed
Older than a year by non-portfolio founder
Unlock more reviews by creating a free account
Solid Folks. Wish We Could Have Come to Terms.
Was directed to Morgenthaler by one of their current venture backed firms and I had really very good impressions of Gary Little and Greg Blonder. They expressed early enthusiasm, but were unsure of our industry. Too bad.
Not reviewed
Team quality
Not reviewed
Investment process
Not reviewed
Value add
Not reviewed
Older than a year by non-portfolio founder
Unlock more reviews by creating a free account
Chris Christoffersen
Chris has an excellent reputation in life sciences/biotech. We have had several discussions with them and they appear engaged and interested. We are meeting with them in January. Will keep you all posted
Not reviewed
Team quality
Not reviewed
Investment process
Not reviewed
Value add
Not reviewed
Older than a year by non-portfolio founder
Unlock more reviews by creating a free account
Morgenthaler Still in Business?
We had an odd experience with Morgenthaler. A friend had told us that Paul Levine was spearheading investment in a market segment where we were focused. We met with him in Burlington and he "loved our concept" and wanted to follow-up. We called and emailed for two weeks with no response. We finally moved on. Paul seemed professional in person, but the radio silence after indicating interest was either rudeness, or ineptness (perhaps both") on his part. They don't seem to be a player anyway.
Not reviewed
Team quality
Not reviewed
Investment process
Not reviewed
Value add
Not reviewed
Older than a year by non-portfolio founder
Unlock more reviews by creating a free account
An Interesting Partnership
There is definitely a dichotomy in this partnership with some of the older, more experienced guys like Bob Pavey who are worth their weight in gold, and guys like Drew Lanza...
Not reviewed
Team quality
Not reviewed
Investment process
Not reviewed
Value add
Not reviewed
Older than a year by non-portfolio founder
Unlock more reviews by creating a free account
Good Feedback but Very Risk Averse
This firm seems very risk averse which is odd as you want to show big returns to LPs and there is this risk/return trade off.
Similar funds